Business WireMerck Expands Colorectal Cancer Portfolio Through License Agreement with Inspirna First-in-class ompenaclide (RGX-202) is currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer. .17 hours ago

3 Responses

Leave a Reply

Your email address will not be published. Required fields are marked *